DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic MelanomaTARGETED ONCOLOGYIF42024-02-248OAAI
Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)ANNALS OF ONCOLOGYIF65.42022-09-011OAAI
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and GermanyJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-02-1926OAAI
Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case reportBRITISH JOURNAL OF DERMATOLOGYIF9.62019-03-2616OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向